Results 21 to 30 of about 735,101 (274)

RETRACTED ARTICLE: Analysis of the factors influencing moderate to poor performance status in patients with cancer after chemotherapy: a cross-sectional study comparing three models

Scientific Reports
There are no models for assessing the factors that determine moderate to poor performance status in patients with cancer after chemotherapy. This study investigated the influencing factors and identified the best model for predicting moderate–poor ...
Ke Xi, Lin Jingping, Liu Yaqing, Yu Xinyuan, Lin Hui, Yang Mei, Chen Qingyue, Liu Dun   +7 more
doaj   +2 more sources

Importance of HER2 Work-Up and Treatment Even in Patients with Poor Performance Status: A Case Report [PDF]

Case Reports in Oncological Medicine, 2014
Gastric cancer is one of most common types of cancers. Metastatic gastric cancer has a poor prognosis and is accepted as incurable at this stage. Treatment of metastatic gastric cancer did not progress substantially until new targeted agents have come ...
Ali Suner, Hakan Buyukhatipoglu, Ozan Balakan, Mehmet Emin Kalender, Turgay Ulas, Alper Sevinc, Celalettin Camci   +6 more
doaj   +2 more sources

Poor Performance Status [PDF]

, 2020
openaire   +2 more sources

Poor performance status reduces efficacy of abiraterone [PDF]

Nature Reviews Urology, 2014
openaire   +2 more sources

Efficacy Survey of Naldemedine in the Poor-performance Status Group

YAKUGAKU ZASSHI, 2022
Naldemedine (Nal) is widely used as a therapeutic drug against opioid-induced constipation. However, patients in phase III trials are limited to those with good performance status (PS). Cancer patients may have inferior PS owing to progression of symptoms and adverse events from chemotherapy.
Shintaro, Kato, Yoshitaka, Saito, Hiroko, Onoda, Masayoshi, Kumai, Shungo, Imai, Kenkichi, Tsuruga, Yoh, Takekuma, Mitsuru, Sugawara   +7 more
openaire   +2 more sources

Utility of immune checkpoint inhibitors in non-small-cell lung cancer patients with poor performance status. [PDF]

Cancer Sci, 2020
Kano H, Ichihara E, Harada D, Inoue K, Kayatani H, Hosokawa S, Kishino D, Watanabe K, Ochi N, Oda N, Hara N, Ninomiya K, Hotta K, Maeda Y, Kiura K.   +14 more
europepmc   +2 more sources

Predicting survival in metastatic non‐small cell lung cancer patients with poor ECOG‐PS: A single‐arm prospective study

Cancer Medicine, 2023
Background Patients with advanced non‐small cell lung cancer (NSCLC) are a heterogeneous population with short lifespan. We aimed to develop methods to better differentiate patients whose survival was >90 days.
Mateus Trinconi Cunha, Ana Paula deSouza Borges, Vinicius Carvalho Jardim, André Fujita, Gilberto deCastro Jr   +4 more
doaj   +1 more source

Management of Patients With Lung Cancer and Poor Performance Status [PDF]

Journal of the National Comprehensive Cancer Network, 2014
Patients who are able to care for themselves but are unable to perform most work-related activities are considered to have a poor performance status (PS). Individuals who fulfill these criteria constitute a significant proportion of all patients with lung cancer.
Ajeet, Gajra, Alissa S, Marr, Apar Kishor, Ganti   +2 more
openaire   +2 more sources

Impact of Performance Status on Survival Outcomes and Health Care Utilization in Patients With Advanced NSCLC Treated With Immune Checkpoint Inhibitors

JTO Clinical and Research Reports, 2023
Introduction: Landmark trials testing immune checkpoint inhibitors (ICIs) in advanced NSCLC are difficult to extrapolate to real-world practice given the exclusion of patients with poor (i.e., ≥2) Eastern Cooperative Oncology Group performance status ...
Daniel E. Meyers, MD, MSc, Meghann Pasternak, MD, MSc, Samantha Dolter, MD, Heidi A.I. Grosjean, MD, Chloe A. Lim, MD, Igor Stukalin, MD, Siddhartha Goutam, MD, Vishal Navani, M.B.B.S., MRCP, Daniel Y.C. Heng, MD, MPH, Winson Y. Cheung, MD, PhD, Don G. Morris, MD, PhD, Aliyah Pabani, MD   +11 more
doaj   +1 more source

Performance status and cytoreductive nephrectomy [PDF]

Cancer, 2008
AbstractBACKGROUND.An Eastern Cooperative Oncology Group performance status (ECOG PS) of 2/3 can quantify cancer patients' well being and may be used to select patients for treatment. The objective of the current study was to investigate the outcomes of cytoreductive nephrectomy (CN) for patients who have an impaired performance status (ECOG PS 2/3 ...
Brian, Shuch, Jeff C, La Rochelle, Jon, Wu, Tobias, Klatte, Stephen B, Riggs, Fairooz, Kabbinavar, Arie S, Belldegrun, Allan J, Pantuck   +7 more
openaire   +2 more sources